Recruiting PHASE2 INTERVENTIONAL 4-arm NCT07170917

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa (BRIGHTEN)

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa

Sponsor: Sanofi

Conditions Hidradenitis Suppurativa

Interventions Brivekimig Placebo

Updated 5 times since 2025 Last updated: Mar 10, 2026 Started: Nov 6, 2025 Primary completion: Aug 1, 2027 Completion: Apr 27, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07170917, this PHASE2 trial focuses on Hidradenitis Suppurativa and remains actively recruiting participants. Sponsored by Sanofi, it has been updated 5 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE2
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antony, France , Atlanta, United States , Baton Rouge, United States , Bezannes, France , Bramsche, Germany , Cadiz, Spain , Chengdu, China , Frankfurt, Germany , Granada, Spain , Groningen, Netherlands and 38 more locations